<DOC>
	<DOCNO>NCT00332930</DOCNO>
	<brief_summary>The objective phase I/II therapeutic human immunodeficiency virus ( HIV ) vaccine candidate study provide proof concept HIV antigen delivery system term safety , virological effect select immune response HIV infect individual cessation antiretroviral combination therapy ( ART ) .</brief_summary>
	<brief_title>ITV Extension Study</brief_title>
	<detailed_description>A multi-centre , double-blind , placebo-controlled , 20-week parallel group extension study VIR-NCHR-01 protocol ( ITV study ) . The purpose extension study assess safety virological effect therapeutic HIV vaccine strategy HIV-1 infect adult currently enrol ITV study cessation antiretroviral therapy . Two active candidate vaccine study trial : The active treatment arm receive recombinant fowlpoxvirus ( rFPV ) express HIV gag-pol antigen HIV gag-pol antigen interferon-gamma ( IFN-y ) diluent . Vaccines deliver intramuscular injection .</detailed_description>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>HIV1 infected individual eligible still fulfil criterion VIRNCHR01 protocol ( ITV study ) Received 3 immunisation Remained followup least 52 week Continued take combination antiretroviral therapy evidence treatment failure time enter rollover phase Written inform consent obtain Criteria Withdrawal Study Participants Incidental progression disease , opinion principal investigator , preclude study participation If study participant require cytotoxic immunosuppressive chemo radiation therapy If study participant require medication combine study vaccination , would opinion principal investigator , jeopardise validity individual ’ continue participation Administration prohibit alternative therapy Study participant noncompliance All study participant require adhere protocol evaluation schedule . Failure adhere schedule without first provide justification may result participant withdrawn study At request study participant principal investigator without prejudice future health care In opinion investigator , patient ’ best interest continue study At request National Centre HIV Epidemiology Clinical Research ( NCHECR ) reasonable cause At advice Data Safety Monitoring Board ( DSMB )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>HIV</keyword>
	<keyword>Therapeutic vaccine</keyword>
</DOC>